- American Association for Cancer Research
- American Gastroenterological Association
- American Society of Clinical Oncology
- Association of VA Hematology/Oncology
David Wang, M.D.
- Internal Medicine - Hematology/Oncology
- Esophageal Cancer
- Gastric Cancer
Biography
David H. Wang, M.D., Ph.D., is an Associate Professor in the Department of Internal Medicine at UT Southwestern Medical Center. He specializes in esophageal and gastric cancer.
Dr. Wang earned his medical degree at Vanderbilt University and a doctorate in cellular and molecular medicine from The Johns Hopkins University. In addition, he completed a residency in internal medicine at Johns Hopkins, where he also received advanced training through a research fellowship in cancer biology and a clinical fellowship in medical oncology. He also spent a year at the National Cancer Institute as a Howard Hughes Medical Institute-National Institutes of Health Research Scholar.
Certified by the American Board of Internal Medicine, Dr. Wang joined the UT Southwestern faculty in 2009.
The author of numerous research articles, book chapters, and invited lectures, Dr. Wang’s clinical and research interests focus on esophageal cancer, gastric cancer, and gastroesophageal junction cancer. His research lab is focused on understanding the role of aberrant developmental pathway signaling in esophageal cancer and precursor lesions. He serves on the National GI Clinical Trials Steering Committee for the U.S. Department of Veterans Affairs.
Dr. Wang is a member of the American Association for Cancer Research, the American Gastroenterological Association, the American Society of Clinical Oncology, and the Association of VA Hematology/Oncology.
Professional Associations & Affiliations
Honors & Awards
- NCI 2006, National Research Service Award
- American Society of Clinical Oncology 2005, Young Investigator Award
- The Endocrine Society 1999, Medical Student Achievement Award
- Howard Hughes Medical Institute 1998, Continued Fellowship for Medical Studies
Books & Publications
-
Publications
-
Cancer-related inflammation and Barrett’s carcinogenesis: Interleukin-6 and STAT3 mediate apoptotic resistance in transformed Barrett’s cells.
HY Zhang, Q Zhang, X Zhang, C Yu, X Huo, E Cheng, DH Wang, SJ Spechler, RF Souza American Journal of Physiology. Gastrointestinal and Liver Physiology. 2011 (In press) -
Biology of Barrett’s esophagus and esophageal adenocarcinoma.
DH Wang, RF Souza Gastrointestinal Endoscopy Clinics of North America January 2011 21 (1) 25-38 -
Malignant transformation of non-neoplastic Barrett’s epithelial cells through well-defined genetic manipulations.
X Zhang, C Yu, K Wilson, HY Zhang, SD Melton, X Huo, DH Wang, RM Genta, SJ Spechler, RF Souza PLOS One September 2010 5 (9) e13093 -
Acid and bile salt-induced CDX2 expression differs in esophageal squamous cells from patients with and without Barrett’s Esophagus.
X Huo, HY Zhang, XI Zhang, JP Lynch, ED Strauch, JY Wang, SD Melton, RM Genta, DH Wang, SJ Spechler, RF Souza Gastroenterology July 2010 139 (1) 194-203 -
Aberrant epithelial-mesenchymal hedgehog signaling characterizes Barrett’s metaplasia.
DH Wang, NJ Clemons, T Miyashita, AJ Dupuy, W Zhang, A Szczepny, IM Corcoran-Schwartz, DL Wilburn, EA Montgomery, JS Wang, NA Jenkins, NA Copeland, JW Harmon, WA Phillips, DN Watkins Gastroenterology May 2010 138(5) 1810-22 -
Epigenetic inactivation of the canonical Wnt antagonist Sry-box containing gene 17 in colorectal cancer.
W Zhang, SC Glockner, M Guo, EO Machida, DH Wang, H Easwaran, L Van Neste, JG Herman, KE Schuebel, DN Watkins, N Ahuja, SB Baylin Cancer Research April 2008 68 (8) 2764-72 -
Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53 dependent DNA damage responses.
WY Chen, DH Wang, RC Yen, J Luo, W Gu, SB Baylin Cell November 2005 123 (3) 437-48 -
A novel Smad nuclear interacting protein, SNIP1, suppresses p300-dependent TGF-β signal transduction.
RH Kim, D Wang, M Tsang, J Martin, C Huff, MP de Caestecker, WT Parks, X Meng, RJ Lechleider, T Wang, AB Roberts Genes and Development July 2000 14 (13) 1605-16 -
The Smad4 activation domain (SAD) is a proline-rich, p300-dependent transcriptional activation domain.
MP de Caestecker, T Yahata, D Wang, WT Parks, S Huang, CS Hill, T Shioda, AB Roberts, RJ Lechleider The Journal of Biological Chemistry January 2000 275 (3) 2115-22
-
Cancer-related inflammation and Barrett’s carcinogenesis: Interleukin-6 and STAT3 mediate apoptotic resistance in transformed Barrett’s cells.
Research
- Barrett's Esophagus
- Esophageal Cancer
- Gastric Cancer
- Hedgehog Signaling
- Molecularly Targeted Therapy
Clinical Focus
- Esophageal Cancer
- Gastric Cancer
- Gastroesophageal Junction Cancer